Completed

Oral vs. Parenteral Dexamethasone for Mild to Moderate Croup in Children

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

oral dexamethasone

+ intramuscular dexamethasone

Drug
Who is being recruted

Croup+2

+ Laryngeal Diseases

+ Laryngitis

From 2 to 12 Years
+8 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
Study Start: October 2024
See protocol details

Summary

Principal SponsorArooj Khan
Last updated: January 30, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: October 1, 2024

Actual date on which the first participant was enrolled.

Croup is a common viral infection in children that leads to a distinctive barking cough and difficulty breathing due to swelling in the throat. This condition primarily affects children between 6 months and 12 years old, with most cases being mild and resolving on their own. However, for cases where treatment is necessary, steroids like dexamethasone are often used to reduce swelling. There is some debate about whether oral or injectable dexamethasone is more effective, especially for mild cases treated outside of hospitals. This study seeks to explore this question further to improve treatment advice and guide future research. In this study, children with mild to moderate croup will receive either oral or injectable dexamethasone. Researchers will observe the children to see how well each form of the medication works in relieving their symptoms. By comparing the effectiveness of the two methods, the study aims to provide clearer guidance on which treatment might be better for managing croup symptoms in non-hospital settings. The goal is to make treatment more effective and ensure children get the best possible care with the least discomfort.

Official TitleEfficacy Of Oral Dexamethasone Versus Parenteral Dexamethasone In The Management Of Mild To Moderate Croup
NCT06959407
Principal SponsorArooj Khan
Last updated: January 30, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

200 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.


Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 2 to 12 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

CroupLaryngeal DiseasesLaryngitisOtorhinolaryngologic DiseasesRespiratory Tract Diseases

Criteria

3 inclusion criteria required to participate
Patient age 2 to 12 years

Both genders

Diagnosed with croup as operational definitions

5 exclusion criteria prevent from participating
Patients with chronic pulmonary disease like tuberculosis,

Allergy or contraindication of corticosteroid (history of tuberous sclerosis, history of varicella infection during the past three weeks), to corticosteroids,

history of corticosteroid administration during the last four weeks,

foreign body

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Active Comparator
Patients in group A will receive oral dexamethasone which will be administered at 0.6mg/kg as single dose

Group II

Active Comparator
Patients in group B will receive intramuscular dexamethasone which will be administered in 0.6mg/kg strength as intra-gluteal injection as single dose

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Khyber Teaching Hospital

Peshawar, PakistanOpen Khyber Teaching Hospital in Google Maps
CompletedOne Study Center